DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Bidard FC, Jacot W, Dureau S. et al.
Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2-metastatic breast cancer: Results of the phase III STIC CTC trial. San Antonio Breast Cancer Symposium; December 4–8, 2018; San Antonio, Texas.
Cancer Res 2019;
DOI: 10.1158/1538-7445.SABCS18-GS3-07.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.